International Clinical Trial: A Prospective, Multicenter, Single-arm Phase II Study Evaluating the Efficacy and Safety of Polatuzumab Vedotin in Combination with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZRCHP) in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma

Geneva, March 23 -- International Clinical Trials Registry received information related to the study (ChiCTR2600119915) titled 'A Prospective, Multicenter, Single-arm Phase II Study Evaluating the Efficacy and Safety of Polatuzumab Vedotin in Combination with Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-ZRCHP) in Previously Untreated Patients with Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma' on March 5.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Condition: Diffuse Large B cell Lymphoma

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026...